| Code |
Title |
|
–
|
Top Categories
|
|
X |
New Technology
|
|
XW |
Anatomical Regions
|
|
XW0
|
Introduction
New Technology, Anatomical Regions, Introduction
|
|
XW01 |
Subcutaneous Tissue
|
|
XW013 |
Percutaneous
|
|
XW0139 |
Satralizumab-mwge
|
|
XW01397
|
New Technology Group 7
Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
|
|
XW013F |
Other New Technology Therapeutic Substance
|
|
XW013F5
|
New Technology Group 5
Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
|
|
XW013H |
Other New Technology Monoclonal Antibody
|
|
XW013H6
|
New Technology Group 6
Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
|
|
XW013K |
Leronlimab Monoclonal Antibody
|
|
XW013K6
|
New Technology Group 6
Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
|
|
XW013S |
COVID-19 Vaccine Dose 1
|
|
XW013S6
|
New Technology Group 6
Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
|
|
XW013T |
COVID-19 Vaccine Dose 2
|
|
XW013T6
|
New Technology Group 6
Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
|
|
XW013U |
COVID-19 Vaccine
|
|
XW013U6
|
New Technology Group 6
Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
|
|
XW013W |
Caplacizumab
|
|
XW013W5
|
New Technology Group 5
Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
|
|
XW01X |
External
|
|
XW01X2 |
Bromelain-enriched Proteolytic Enzyme
|
|
XW01X27
|
New Technology Group 7
Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7
|